Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Entinostat + Medroxyprogesterone |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Entinostat | HDAC inhibitor SNDX-275|MS 275 | HDAC Inhibitor 45 | Entinostat (MS-275) inhibits HDAC activity, with selectivity towards HDAC1, 2, and 3, which results in increased histone acetylation, and potentially leads to decreased tumor cell proliferation and tumor growth (PMID: 19724929, PMID: 17383217, PMID: 32503469). | |
Medroxyprogesterone | Depo-Provera | CBP-1011 | Hormone - Anti-estrogens 29 | Depo-Provera (medroxyprogesterone) is a synthetic progesterone derivative that acts as an anti-estrogen by binding to and activating nuclear receptors, stimulating downstream signaling and potentially resulting in decreased growth of estrogen-sensitive tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03018249 | Phase II | Medroxyprogesterone Entinostat + Medroxyprogesterone | Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer | Completed | USA | 0 |